Mean platelet volume linked to mortality in peritoneal dialysis patients
Nov 22, 2023
MPV ≥10.2 fL was independently associated with all-cause mortality and cardiovascular mortality.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Remission of type 2 diabetes feasible with soup and shake diet intervention
Aug 09, 2024
32% of those who completed the program had remission, with mean weight loss of 14.4%, or 15.9 kg.
Long-term low-carb diet efficacious for treating dyslipidemia in T2D
Aug 02, 2024
However, no significant differences were seen in changes in glycated hemoglobin between long-term low-carb and control diets.
FDA warns of accidental overdoses from compounded versions of Ozempic
Jul 30, 2024
(HealthDay News) — People taking compounded versions of Ozempic have been overdosing on the drug, the US Food and Drug Administration warns. These ODs typically are due to miscommunications or miscalculations...
Aging into Medicare tied to higher drug costs for people with diabetes
Jul 17, 2024
Quarterly out-of-pocket costs increased by approximately $23, on average, after age 65.
New report calls for more research on women’s health issues
Jul 12, 2024
The National Academies of Sciences, Engineering and Medicine analysis noted that women are disproportionately affected by chronic illnesses, including Alzheimer’s disease, depression and osteoporosis.
Significantly more weight loss seen with tirzepatide versus semaglutide
Jul 08, 2024
Patients with overweight or obesity receiving tirzepatide were significantly more likely to achieve ≥5, ≥10 and ≥15% weight loss.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Coverage for Medicare’s e-visits still available, though few patients use service
By
Kristen Fischer
Apr 16, 2024
E-visits, which drew expanded coverage during the pandemic still are available but not used often, a new study shows.